Search PURE
PURE BIOSCIENCE, INC.
OTC · CIK 1006028
Last close0.06
Daily change-0.01 (-14.29%)
10 Years gain-94.59%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PURE · STANDARD
SIC 2890 · Miscellaneous Chemical Products · Fiscal year end 0731
Fundamental
68.2Momentum
100.0Acceleration
100.0Confidence
90.0Annual Revenue15
Quarterly Revenue55
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.7 / 25
Quality18.7 / 25
Capital Efficiency20.0 / 20
Balance Sheet8.1 / 15
Shareholder Economics6.4 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 53.3299 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 0.915%.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM15.41%OK
Revenue CAGR 3Y5.92%OK
Gross Margin57.7%OK
Operating Margin-100.7%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y541.74%OK
Net Debt / CFO0.54xOK
Diluted Share Growth 1Y-0.92%OK
SBC / Revenue8.38%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Jul 31, 2025 | $2.20M | $1.30M | -$2.27M | -$2.02M | n/a | 59.17% | -103.18% | n/a | n/a | 111.86M |
| 2025 FY Jul 31, 2024 | $1.96M | $1.15M | -$3.19M | -$2.53M | n/a | 58.69% | -162.56% | n/a | n/a | 111.86M |
| 2024 FY Jul 31, 2023 | $1.88M | $971,000.00 | -$3.94M | -$3.28M | -$3.31M | 51.73% | -210.07% | -176.4% | n/a | 111.4M |
| 2023 FY Jul 31, 2022 | $1.85M | $1.00M | -$3.72M | -$2.42M | -$2.50M | 53.97% | -200.97% | -134.86% | -402.73% | 88.84M |
| 2022 FY Jul 31, 2021 | $3.93M | $2.08M | -$2.31M | -$1.17M | -$1.69M | 52.84% | -58.85% | -42.98% | -190.67% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.15M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-028691, 0001493152-25-027749 |
| Revenue Growth TTM | 15.41% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-028691, 0001493152-25-027749 |
| Revenue CAGR 3Y | 5.92% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-25-020065 |
| Revenue CAGR 5Y | -20.46% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-25-020065 |
| Gross Profit CAGR 3Y | 9.22% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-25-020065 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-028691, 0001493152-25-027749 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 57.7% | Gross Profit / Revenue | OK | 0001493152-26-028691, 0001493152-25-027749 |
| Operating Margin | -100.7% | Operating Income / Revenue | OK | 0001493152-26-028691, 0001493152-25-027749 |
| Net Debt / CFO | 0.54x | Net Debt / CFO | OK | 0001493152-26-028691, 0001493152-26-010385 |
| Current Ratio | 0.42x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 8.38% | SBC / Revenue | OK | 0001493152-26-028691, 0001493152-25-027749 |
| Revenue per Diluted Share | $0.02 | Revenue / Diluted Shares | OK | 0001493152-26-028691, 0001493152-25-027749 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001493152-26-028691, 0001493152-25-027749 |